Pfenex is a leading-edge biologics company driven by the desire to provide access to safe, effective, affordable products to market.
We have the highest-quality protein production and bioanalytic technology platform approach that allows us to create biosimilars in a highly efficient manner from concept to commercialization.
We are one of the only companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This focus allows us to ensure a robust pipeline of high-quality therapeutics.
In addition, our unique protein production platform is well suited to vaccine development. By capitalizing on our ability to rapidly identify production strains for proteins that cannot be readily produced in other systems we are able to conduct infectious disease research and vaccine development previously not possible.